A Simple Blood Test Detects Suicidal Tendencies in Individuals with Major Depressive Disorder
|
By LabMedica International staff writers Posted on 06 May 2022 |
|
A gene expression signature found in blood and brain tissue from individuals with major depressive disorder seemed to be associated with the likelihood of development of suicidal behavior.
Suicide is a serious global public health problem that accounts for close to 800,000 deaths per year, and since major depressive disorder (MDD) is the most common diagnosis among suicides, identifying those at the highest risk for suicide is a pressing challenge.
To meet this challenge, investigators at the University of California, Irvine (USA) collected blood and dorsolateral prefrontal cortex (DLPFC) samples from MDD patients who died by suicide (MDD-S), MDDs who died by other means (MDD-NS), and non-psychiatric controls. Gene expression was analyzed using RNA and the NanoString (Seattle, WA, USA) platform.
Results revealed 14 genes in the blood samples that significantly differentiated MDD-S versus MDD-NS. The top six genes differentially expressed in blood were: PER3, MTPAP, SLC25A26, CD19, SOX9, and GAR1. Additionally, four genes showed significant changes in brain and blood between MDD-S and MDD-NS; SOX9 was decreased and PER3 was increased in MDD-S in both tissues, while CD19 and TERF1 were increased in blood but decreased in DLPFC. These changes in gene expression reflected stress response, including polyamine metabolism, circadian rhythm, immune dysregulation, and telomere maintenance.
“These blood biomarkers are an important step toward developing blood tests to identify patients with imminent risk of ending their lives,” said senior author Dr. Adolfo Sequeira, associate researcher in the department of psychiatry and human behavior at the University of California, Irvine. “To our knowledge, this is the first study to analyze blood and brain samples in a well-defined population of MDDs demonstrating significant differences in gene expression associated with completed suicide.”
The study was published in the April 14, 2022, online edition of the journal Translational Psychiatry.
Related Links:
University of California, Irvine
NanoString
.jpg)
Latest Molecular Diagnostics News
- Blood Test Maps Tumor Microenvironment to Predict Immunotherapy Response
- Liquid Biopsy Biomarkers Distinguish Inflammatory Breast Cancer and Support Monitoring
- Multiplex Respiratory Panel Integrates Automated Extraction to Streamline High-Volume Testing
- Whole-Blood RNA Test Predicts Disease Trajectory and Treatment Response
- Blood-Based Epigenetic Test Predicts GLP-1 Response and Tracks Treatment Effects
- Tumor Genomic Testing Guides Immunotherapy Selection in Pituitary Tumors
- Liquid Biopsy Predicts Immunotherapy Response in Breast Cancer
- New Blood Test Distinguishes Pancreatic Cancer From Benign Disease
- Noninvasive Test Confirms High-Risk Prenatal Screening Results from Blood
- Machine-Learning Genetic Risk Score Improves Early Prediction of Type 1 Diabetes
- Rapid Tongue Swab Molecular Test Detects Pulmonary Tuberculosis at Point of Care
- CRISPR-Based Test Identifies Multiple Respiratory Viruses Simultaneously
- Blood Test Receives FDA Breakthrough Status to Differentiate Schizophrenia and Bipolar Disorder
- Portable Test Detects Tuberculosis from Tongue Swabs in 30 Minutes
- Multi-Omic Assay Predicts Recurrence and Radiation Benefit in Early Breast Cancer
- Genomic Risk Score Identifies Inherited Risk for Multiple Cardiovascular Conditions
Channels
Clinical Chemistry
view channel
Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
Dementia affects more than 57 million people worldwide and is projected to nearly double within two decades, straining health systems and families. While biomarkers now enable accurate identification of... Read more
Routine Blood Tests Years Before Pregnancy Could Identify Preeclampsia Risk
High blood pressure during pregnancy is common and can progress to pre-eclampsia, making close monitoring at antenatal visits essential. However, most risk assessment begins only after pregnancy has started.... Read more
Hematology
view channel
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more
Blood Test Enables Early Detection of Multiple Myeloma Relapse
Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read more
Immunology
view channel
Point-of-Care Tests Could Expand Access to Mpox Diagnosis
Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read more
T-Cell Senescence Profiling May Predict CAR T Responses
Chimeric antigen receptor (CAR) T-cell therapy can deliver striking, durable remissions, yet many patients experience minimal or no benefit. The quality of patient-derived cytotoxic T lymphocytes used... Read more
Microbiology
view channel
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read more
Pathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read more
Technology
view channel
Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read more
New Platform Captures Extracellular Vesicles for Early Cancer Detection
Early diagnosis remains the most effective way to reduce cancer mortality, yet many screening tools miss disease at its earliest stages. Biomarkers shed by tumors into blood and other fluids can be scarce... Read more
Industry
view channel
Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more
